Predicine, a Hayward, Calif.-based precision medicine company, today announced it has completed its $13.5M Series A financing from Sangel Capital, Rongsheng Investment, and Highlight Capital. Predicine provides an integrated oncology biomarker solution that includes an innovative RNA+DNA liquid biopsy test and a one-stop biomarker and data analysis platform to support targeted cancer therapeutics and global clinical...